AMC Entertainment heads into its Q1 2026 earnings today with short sellers actively rebuilding positions — making the lending market the sharpest lens through which to read current sentiment.
Short interest has climbed for five consecutive sessions, rising 10% over the past week alone to reach roughly 17.7% of the free float. That reverses a sharp unwind from April — when SI shed nearly 20% over the month from a peak above 21% — suggesting a fresh wave of bearish positioning rather than a sustained squeeze unwind. The borrow market tells a compatible story: availability has tightened to around 49%, meaning less than one share remains in the lending pool for every two already borrowed. Cost to borrow, at 1.28%, has more than doubled over the past month, though it remains low in absolute terms. The ORTEX short score of 68 places AMC in the bottom 6th percentile of the universe for short-side pressure — elevated, but not at the extremes the stock saw earlier in April when availability briefly collapsed to zero.
Options traders, by contrast, are not particularly defensive. The put/call ratio of 0.18 is slightly below its 20-day average and well off the 52-week high of 0.31, implying call activity still dominates. The stock has shed 12% over the past week to $1.45, giving back most of a 29% gain posted over the prior month — a reminder of how volatile the name remains at these price levels.
The bull and bear cases heading into the print are well defined. Bulls point to a projected improvement in EBITDA margins — from roughly 8% in 2025 toward 12% by 2027 — and a blockbuster film slate in 2026 that could drive box office attendance higher. Net leverage has improved to 9.3x and the company expects it to trend toward 7x by year-end, a material step for a balance sheet that remains stretched. Bears see a more sobering picture: an adjusted EBITDA loss still projected at around $7 million, declining attendance weighing on high fixed-cost theatres, and a valuation that quant models flag as stretched relative to peers. The Street's recent direction has been consistently negative — Macquarie, Citigroup, and Roth Capital all trimmed targets in February, with Citi holding a Sell and a $1.10 target against the current price of $1.45. The mean analyst target of $1.92 sits modestly above the current price, but the trajectory of revisions has been downward for over a year.
At $1.45, with short interest climbing back toward its recent peak and availability tightening fast, the Q1 report is ultimately a test of whether any tangible progress on EBITDA and attendance can interrupt the pattern of analyst target cuts — or whether the fresh short buildup proves well-timed.
See the live data behind this article on ORTEX.
Open AMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
